LEU-001

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLEU-001
Drug Alias NameT1E28zLEU-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor tyrosine-protein kinase erbB modulatorsT lymphocyte replacements
TargetsReceptor tyrosine-protein kinase erbB
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKing'S College London
China Registration ClassN/A

Develop Information

Active CompaniesLeucid BioKing'S College London
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A